ALK-Abelló Temettü

Temettü kriter kontrolleri 0/6

ALK-Abelló şu anda temettü ödemiyor.

Anahtar bilgiler

Temettü verimi

-0.006%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-0.006%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	€0.250
Ödeme oranı	0%

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: 4AJ0 şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: 4AJ0 şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

ALK-Abelló Piyasaya Karşı Temettü Getirisi

4AJ0 temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (4AJ0)	0%
Pazarın Alt %25'i (DE)	1.6%
Pazarın En İyi %25'i (DE)	4.8%
Sektör Ortalaması (Pharmaceuticals)	1.2%
Analist tahmini (4AJ0) (3 yıla kadar)	0%

Önemli Temettü: 4AJ0 şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, 4AJ0 şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: 4AJ0 German piyasası için dikkate değer bir temettü ödemiyor.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: 4AJ0 herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

ALK-Abelló Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

ALK Announces U.S. FDA Approval of New AccuTest Allergy Skin Testing Devices for Optimized Allergy Testing and Diagnosis

Second quarter 2024 earnings released: EPS: kr.0.90 (vs kr.0.30 in 2Q 2023)

ALK-Abelló A/S Revises Earnings Guidance for the 2024

Now 20% undervalued after recent price drop

ALK Presents Positive Phase 3 Paediatric Trial Data Offering New Hope for Children with Respiratory Allergy

Now 20% undervalued

Alk's European Registration Application for Itulazax for Pneumiatric Indication Accepted for Review

Now 20% undervalued

Investor sentiment improves as stock rises 22%

First quarter 2024 earnings released

ALK-Abelló A/S Updates Revenue Guidance for the Year 2024

Insider recently sold €1.2m worth of stock

Full year 2023 earnings released

Alk-Abelló A/S Provides Revenue Guidance for the Year of 2024

Alk's European Registration Application for House Dust Mite Slit-Tablet in Young Children Accepts for Review

ALK-Abelló A/S Completes First Part of Phase 1 Trial with Peanut Slit-Tablet

ALK-Abelló A/S to Report Q2, 2024 Results on Aug 23, 2024

ALK-Abelló A/S to Report Fiscal Year 2023 Results on Feb 08, 2024

Third quarter 2023 earnings released: EPS: kr.0.50 (vs kr.0.20 in 3Q 2022)

Investor sentiment improves as stock rises 18%

Alk-Abelló A/S Provides Earnings Guidance for the Year 2023

ALK Announces Top-Line Results from A Phase 3 Pneumiatric Clinical Trial of Its Sublingual Allergy Immunotherapy Tablet for the Treatment of Tree-Pollen-Induced Allergy Immunotherapy Tablet

ALK-Abelló A/S Narrows Revenue Guidance for the Full Year 2023

Investor sentiment deteriorates as stock falls 17%

Alk-Abelló A/S Announces Executive Changes

Alk Announces Top-Line Results from A Phase 3 Paediatric Clinical Trial of Its Sublingual Allergy Immunotherapy Tablet for the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis

ALK-Abelló A/S Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings released

Now 26% undervalued after recent price drop

ALK Announces Management Changes

Full year 2022 earnings released

ALK-Abelló A/S Provides Revenue Guidance for the Full Year 2023

U.S. FDA Approves ALK's ODACTRA® (House Dust Mite Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Adolescents

ALK-Abelló A/S Announces Executive Changes

ALK-Abelló A/S, Annual General Meeting, Mar 23, 2023

ALK Announces Resignation of Søren Jelert as CFO, Effective May 31, 2023

Less than half of directors are independent

Third quarter 2022 earnings released

ALK-Abelló A/S Provides Earnings Guidance for the Year 2022

Second quarter 2022 earnings released

ALK-Abelló A/S Provides Earnings Guidance for the Year 2022

ALK Begins Clinical Trial Of Its Slit-tablet For The Treatment Of Peanut Allergy

Now 24% undervalued after recent price drop

Alk-Abelló A/S Announces Executive Changes

Now 21% undervalued

First quarter 2022 earnings released

ALK-Abelló A/S Provides Earnings Guidance for the Year 2022

Less than half of directors are independent

ALK Expects to Submit Registration Application in China for its House Dust Mite (HDM) Sublingual Allergy Immunotherapy (Slit) Tablet Already in 2022

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Full year 2021 earnings: Revenues in line with analyst expectations

ALK-Abelló A/S Provides Earnings Guidance for the Fiscal Year 2022

ALK-Abelló A/S Provides Earnings Guidance for the Fiscal Year 2022

ALK-Abelló A/S Announces Results from the REACT Study

Third quarter 2021 earnings released

Second quarter 2021 earnings released

ALK-Abelló A/S Revises Earnings Guidance for the Full-Year of 2021

ALK-Abelló A/S (CPSE:ALK B) acquired OTIPRIO from Otonomy, Inc. (NasdaqGS:OTIC).

First quarter 2021 earnings released

ALK Provides Earnings Guidance for the Year 2021

Revenue misses expectations

New 90-day high: €364

Full year 2020 earnings released

New 90-day high: €344

ALK-Abelló A/S to Report Q2, 2021 Results on Aug 11, 2021

New 90-day high: €309

Revenue misses expectations

New 90-day high: €306

ALK Announces ITULATEK Sublingual Allergy Immunotherapy (Slit)-Tablet

ALK-AbellÃ³ A/S to Report Q3, 2010 Results on 11/16/2010

Earnings released

New 90-day high - €257

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi